Oppenheimer Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $9

Written by Emily J. Thompson, Senior Investment Analyst

PRQR-1.23%

Source: Benzinga

Updated: May 13 2025

0mins

Source: Benzinga

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like PRQR with instant alerts to capture every critical market movement.

Sign up for free to build your custom watchlist and receive professional-grade stock notifications.

PRQR

$1.6+Infinity%1D

Analyst Views on PRQR

Wall Street analysts forecast PRQR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRQR is 7.60 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Analyst Rating

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.620

Low

4.00

Averages

7.60

High

12.00

Current: 1.620

Low

4.00

Averages

7.60

High

12.00

Evercore ISI

Outperform

maintain

$4 -> $5

2025-07-11

Reason

Evercore ISI

Price Target

$4 -> $5

AI Analysis

2025-07-11

maintain

Outperform

Reason

Evercore ISI raised the firm's price target on ProQR Therapeutics to $5 from $4 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a "notable lengthening" of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.

Oppenheimer

Andreas Argyrides

Outperform

downgrade

$15 -> $9

2025-05-13

Reason

Oppenheimer

Andreas Argyrides

Price Target

$15 -> $9

2025-05-13

downgrade

Outperform

Reason

Oppenheimer analyst Andreas Argyrides lowered the firm's price target on ProQR Therapeutics to $9 from $15 and keeps an Outperform rating on the shares following quarterly results. The firm notes lead program/AX-0810 for cholestatic diseases remains on track for a 2Q25 CTA submission followed by topline data in Q4 2025 from the healthy volunteers study. Oppenheimer expects clinical candidate selection in 2025 for AX-2402/Rett Syndrome and AX-2911/MASH followed by trial initiations and topline readouts in 2026. The firm sees ProQR's initial clinical data and 2025 RNA editing catalysts re-igniting investor interest. While its fundamental outlook remains intact, negative sector sentiment continues to weigh heavily on early clinical-stage companies with no clinical data, as such, Oppenheimer increases the discount rate from 30% to 40%.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PRQR

Unlock Now

About PRQR

ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for PRQR?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy PRQR?

Get Started Free

Top News

Oppenheimer Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $9

Get Free Real-Time Notifications for Any Stock

Analyst Views on PRQR

About PRQR

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

ArcelorMittal Signs Mineral Development Agreement with Liberia

Anfield Energy Amends Credit Facility Agreement for Acquisition

Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading

VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch